RESUMO
BACKGROUND: In patients with chronic stable coronary artery disease (CAD), welldeveloped coronary collateral circulation (CCC) is known to reduce longterm mortality. AIMS: The objective of this study was to determine the relationship of serum calprotectin (S100A8 / S100A9), angiopoietin1 (Ang1) and angiopoietin2 (Ang2) concentrations with CCC in patients with stable CAD. METHODS: This prospective crosssectional study included 147 patients with stable angina pectoris. The Cohen-Rentrop classification was used to assess CCC. Patients were divided into 2 groups: with poor CCC (Cohen-Rentrop score, 0-1; n = 79) and with good CCC (Cohen-Rentrop score, 2-3; n = 68). Serum calprotectin, Ang1, and Ang2 concentrations were compated between groups. RESULTS: Compared with the group with good CCC, serum calprotectin and Ang1 levels were higher (P <0.01 and P <0.001, respectively), while serum Ang2 levels were lower (P <0.01) in the poorCCC group. Creactive protein levels showed a moderate positive correlation with calprotectin levels (r = 0.359; P <0.001). In a multivariate regression analysis, only calprotectin (P <0.05) and Ang1 (P <0.05) were found to be independent predictors of good and poor CCC. CONCLUSIONS: Our study showed that Ang2 levels were lower, while serum calprotectin and Ang1 levels were higher, in patients with stable CAD and poor CCC regardless of the complexity and severity of coronary arteriosclerosis. If these results are confirmed in future studies, calprotectin may be considered a useful biomarker for guiding antiischemic treatment.